Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chaosu Hu
Observed names:
C S Hu,
C. Hu,
Changzhao Hu,
Chao-Su Hu,
Chao‐Su Hu
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Zhejiang Provincial People's Hospital,
Shanghai Clinical Research Center,
Hangzhou Medical College
show all 6
ORCID:
0000-0001-6407-3311
Observed ORCID:
0000-0001-6407-3311
OpenAlex ID:
A5079423095
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
2021
·
Yunpeng Yang
, Song Qu
, et al.
·
The Lancet Oncology
·
519
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma
2021
·
Ling‐Long Tang
, Yu‐Pei Chen
, et al.
·
癌症:英文版
·
466
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial
2023
·
Hai-Qiang Mai
, Qiu-Yan Chen
, et al.
·
JAMA
·
330
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
2023
·
Yunpeng Yang
, Jianji Pan
, et al.
·
Cancer Cell
·
271
PDF
The impact of training sample size on deep learning-based organ auto-segmentation for head-and-neck patients
2021
·
Yingtao Fang
, Jiazhou Wang
, et al.
·
Physics in Medicine and Biology
·
75
PDF
Effect of Dosimetric Factors on Occurrence and Volume of Temporal Lobe Necrosis Following Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma: A Case-Control Study
2014
·
Xin Zhou
, Xiaomin Ou
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
63
Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
2023
·
Xiaomin Ou
, Ruiping Zhai
, et al.
·
Clinical Cancer Research
·
52
JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
2021
·
Rui-hua Xu
, Hai-Qiang Mai
, et al.
·
Journal of Clinical Oncology
·
32
Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study
2023
·
Ting Liu
, Di Dong
, et al.
·
BMC Medicine
·
30
PDF
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study
2024
·
Xiaozhong Chen
, Wei Wang
, et al.
·
Signal Transduction and Targeted Therapy
·
29
CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
2023
·
Ye Wei
, Tingting Xu
, et al.
·
Cancer Immunology Research
·
26
Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes
2023
·
Wen-Sa Peng
, Xing Xing
, et al.
·
Oral Oncology
·
20
LAPTM4B knockdown increases the radiosensitivity of EGFR-overexpressing radioresistant nasopharyngeal cancer cells by inhibiting autophagy
2019
·
Chu Chu
, Xiaoshuang Niu
, et al.
·
OncoTargets and Therapy
·
20
PDF
Interplay of Tumor Spread, Volume and Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: Feasibility of An Integrative Risk Stratification Scheme
2018
·
Xin Zhou
, Youqi Yang
, et al.
·
Journal of Cancer
·
19
PDF
Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01)
2023
·
Tingting Xu
, Chunying Shen
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
17
PDF
Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy
2023
·
Wenbin Yan
, Chunhua Sun
, et al.
·
Cancer Imaging
·
15
PDF
The impact of target dosimetry on patients’ locoregional recurrence in nasopharyngeal carcinoma: A propensity score-matched analysis
2019
·
Jiazhou Wang
, Gan Qing
, et al.
·
Radiotherapy and Oncology
·
15
121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
2021
·
Y. Yang
, J. Pan
, et al.
·
Annals of Oncology
·
14
AntiPD-L1 antibody conjugated Au-SPIOs nanoplatform for enhancing radiosensitivity and triggering anti-tumor immune response
2022
·
Chengrun Du
, Jianyun Jiang
, et al.
·
Scientific Reports
·
12
PDF
Tumor cell-derived exosomal miR-193b-3p promotes tumor-associated macrophage activation to facilitate nasopharyngeal cancer cell invasion and radioresistances
2024
·
Weiwei Li
, Xing Xing
, et al.
·
Heliyon
·
11
Is postoperative radiotherapy an essential treatment for nonmetastatic lymphoepithelial carcinoma of the salivary gland?
2022
·
Xiaoshuang Niu
, Peiyao Liu
, et al.
·
Radiotherapy and Oncology
·
11
PDF
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study
2026
·
Shuang Huang
, Feng Liu
, et al.
·
Signal Transduction and Targeted Therapy
·
10
PDF
Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
2025
·
Chaosu Hu
, Xiaozhong Chen
, et al.
·
Cancer Research
·
10
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study
2023
·
Xiaoshuang Niu
, Peiyao Liu
, et al.
·
Translational Oncology
·
10
Radiation therapy-induced reactive oxygen species specifically eliminates CD19+ IgA+ B cells in nasopharyngeal carcinoma
2019
·
Weiwei Li
, Luman Wang
, et al.
·
Cancer Management and Research
·
10
PDF
Show more works
View as search
Works count:
117
Citation count:
2,249
H-index:
15
I10-index:
25
Year
Topic
Type